Abstract: Compounds of the formula ##STR1## wherein R.sub.3, R.sub.4, J, K, Z, and Het are as set forth herein are described.The compounds of formula I are useful as agents in the treatment of fungal infections.

Abstract: Disclosed herein are compounds of the formula ##STR1## wherein R.sub.1, R.sub.3, R.sub.4, R.sub.11, and c are as set forth herein are described. These compounds are useful as agents for the treatment of mammals infected with herpes group virus. Certain of these compounds are useful as antitumor agents.

Abstract: The invention relates to compounds of the formulas ##STR1## wherein R.sub.1, R.sub.2, X and Z are as described herein. These compounds are useful as antitumor agents.

Abstract: The invention relates to compounds of the formula ##STR1## wherein X, Y, Z, R.sub.1, R.sub.2, R.sub.4, and R.sub.5, are as described herein. These compounds are useful as agents for the treatment of inflammation, tumors and psoriasis.

Abstract: Topical compositions in gel form for the treatment of corns and calluses comprising a 7 to 13 carbon dicarboxylic acid and a pharmaceutically acceptable carrier, are described.

Abstract: Disclosed is a compound of Formula I: ##STR1## or a pharmaceutically acceptable salt or solvate thereof. Also disclosed are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an effective amount of a Compound of Formula I.Further disclosed is a method of treating allergy (for example asthma), inflammation, hypertension, raised intraocular pressure (such as glaucoma)--i.e., a method of lowering intraocular pressure, sleeping disorders, states of hyper and hypo motility and acidic secretion of the gastrointestinal tract, hypo and hyperactivity of the central nervous system (for example, agitation and depression) and other CNS disorders (such as Alzheimers, Schizophrenia, and migraine) comprising administering an effective amount of a compound of Formula I to a patient in need of such treatment.

Abstract: A compound of formula I ##STR1## wherein X, V, W, Y, Z, R, a, b, c, and d are as described herein. These compounds are useful in the treatment of tumors, allergies, bronchoconstriction and CNS diseases and conditions.

Abstract: Compounds of the formulas I and II ##STR1## and pharmaceutically acceptable salts thereof, wherein R.sub.1, R.sub.3, R.sub.4, R.sub.6, R.sub.8, and R.sub.9 are as set forth herein, are described. These compounds are useful as agents for treating patients afflicted with a herpes group virus. Certain of these compounds are also useful as antitumor agents.

Abstract: The invention relates to compounds of the formula ##STR1## wherein Z, X, Q, Y, W, and W' are as described herein. These compounds have antiviral activity, and certain of these compounds have antiinflammatory activity and are PAF inhibitors.

Abstract: Apparatus for performing immunoassays which is essentially self-contained, requiring only the introduction of a sample and, at appropriate times, washing solution. The apparatus (10) includes: a fluid container (12) having a central platform area with a reaction area (30) which can contain a reactive agent; a sample receiving chamber (22) having a sample conduit (24) located above the porous medium; at least one openable reagent container (46); a conduit (28) for directing reagents onto the porous medium; an opening member (50) attached to the upper unit and positioned to contact and open reagent containers sequentially, by incremental relative rotation of the upper and base units; and a window (34) for viewing the reaction area. The apparatus can also include a sampler member (58) in the nature of a tampon for assays involving samples taken from body cavities.

Abstract: 7-Chloro-8-methoxytetracycline isolated from antibiotic ES-119 and antibiotic Tet. 7 which are produced by fermentation of mutants of Actinomadura brunnea, namely Actinomadura brunnea var. antibiotica, ATCC 53108 and Actinomadura brunnea var antibiotica ATCC 53180 and its use as an antibiotic against gram-positive and gram-negative organisms are disclosed.

Abstract: A powder dispenser 10 includes a powder housing 28 for holding a supply of powdered material to be dispensed, the powder housing including a first conduit 32 extending there through in displaced relation to the powdered material; a metering plate 16 having only a single receptacle area 24 for holding a metered amount of the powdered material above a gas-permeable powder retainer 26 mounted at the metering plate, and being positioned below the powdered material, and the metering plate and the powder housing being rotatable with respect to each other so that the receptacle area is adapted to be in selective communication with the supply of powdered material or the first conduit; a base housing 48 being mounted below the metering plate and including a second conduit 52 in alignment with the first conduit at least concurrently with alignment of the receptacle area and the first conduit; a spring 62 for biasing the base housing and the powder housing toward each other; a mouthpiece 92 for enabling inhalation of th

Abstract: Biological material is entrapped in a hydrophilic gel by using an apparatus containing a biphasic spray head. In a preferred embodiment, mammalian cells are mixed with a solution of alginate to form a mixture and the mixture is fed to a biphasic spray head where the mixture passes through a nozzle surrounded by an annular passageway through which air is passed. Droplets of the mixture are formed at the tip of the nozzle and air passing through the passageway frees the droplets from the tip and propels them into the atmosphere in the form of fine spherical droplets. The droplets then contact a solution of divalent cation such as calcium chloride which gels the alginate. Preferably, the nozzle has an inner diameter of between about 0.006" and 0.016" and is beveled at an angle between about 15.degree. and 30.degree. to form a conical tip.

Abstract: Compounds useful as antiviral agents against DNA-containing viruses, such as herpes group viruses, are disclosed. The compounds are represented by Formula 1.0: ##STR1## and their pharmaceutically acceptable salts and solvates; wherein:(A) X is selected from the group consisting of N--R.sup.3, O, S, and C(R.sup.3).sub.2 ;(B) R.sup.3 is selected from H and a range of substituents;(C) R.sup.1 is an etherifying or esterifying group;(D) R.sup.2 is selected from a range of substituents;(E) m is 0 or an integer from 1 to 4; and(F) R.sup.4 and R.sup.5 are the same and are selected from alkyl and acyl groups;together with the pharmaceutically acceptable salts of the compounds of Formula 1.0 that are acidic or basic.Pharmaceutical compositions containing compounds represented by Formula 1.0 are disclosed. Also disclosed are methods of treating a viral infection using compounds represented by Formula 1.0.